Results 161 to 170 of about 93,929 (247)

Astragaloside IV Reduces Sorafenib-Induced Cardiotoxicity by Inhibiting Apoptosis Through the STAT3/HIF-1α/Bcl-2 Signaling Pathway. [PDF]

Int J Mol Sci
Wang L, Liu B, You Q, Cai H, Huang T, Lei Y, Wang H, Yao Y, Shao S, Guo H.   +9 more
europepmc   +1 more source

Mediation Analysis With Bayesian Nonlinear Joint Models: Evaluation of the Treatment Causal Pathways Between Tumor Growth Kinetics and Overall Survival

Statistics in Medicine, Volume 45, Issue 13-14, June 2026.
ABSTRACT Understanding the mechanisms through which anti‐cancer treatments influence survival is central to improving drug development and evaluation. In this work, we develop a Bayesian joint modeling framework for mediation analysis to quantify the extent to which tumor size dynamics mediate the effect of treatment on overall survival (OS). Our model
Georgios Kazantzidis, Francois Mercier, Virginie Rondeau   +2 more
wiley   +1 more source

The Antihistamine Astemizole Potentiates the Antitumor Efficacy of Sorafenib in Hepatocellular Carcinoma by Suppressing Proliferation, Metastasis, and Angiogenesis. [PDF]

Curr Issues Mol Biol
Zhang Y, Chen X, Yang X, Wang P, Zhang X, Kong D, Wang R.   +6 more
europepmc   +1 more source

Sorafenib for advanced and refractory desmoid tumors [PDF]

, 2018
Van Tine, Brian A.
core   +1 more source

Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High‐Risk Hematological Malignancies

European Journal of Haematology, Volume 116, Issue 6, Page 907-914, June 2026.
ABSTRACT Introduction Allogeneic stem cell transplantation (allo‐SCT) and donor lymphocyte infusions (DLI) can elicit a graft‐versus‐leukemia (GvL) effect in pediatric patients with hematological malignancies. We report our single‐center experience with prophylactic DLI in high‐risk pediatric patients with leukemia or lymphoma, focusing on feasibility,
Denise Epple, Katja Gall, Luisa Paschke, Hans‐Jochem Kolb, Angela Wawer, Hans Knabe, Irene von Luettichau, Julia Hauer, Uwe Thiel   +8 more
wiley   +1 more source

(<i>E</i>)-4-(4-Acrylamidophenoxy)-<i>N</i>-Methylpicolinamides as b-Raf/VEGFR-2 Inhibitors with Antiangiogenic Activity in HUVEC and Zebrafish Model. [PDF]

Molecules
Velma GR, Telukutla SR, Vankudoth J, Grewal AS, Privér S, Yedla P, Akunuri R, Wlodkowic D, Pabbaraja S, Bhargava SK, Plebanski M, Kamal A.   +11 more
europepmc   +1 more source

From Theory to Practice: Which Biomarkers Are Ready for Predicting Response in Advanced HCC?

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Systemic therapies for advanced hepatocellular carcinoma (HCC) have expanded considerably with the advent of tyrosine kinase inhibitors, immune checkpoint inhibitors and immunotherapy–anti‐angiogenic combinations. However, despite this therapeutic diversification, first‐line treatment selection remains largely empirical, as few biomarkers are ...
Marie Decraecker, Jean‐Frédéric Blanc, Samuel Amintas, Grégoire Manaud   +3 more
wiley   +1 more source

Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma. [PDF]

Curr Oncol Rep
Wysocki PT, Chmiel P, Jassem J, Kraj L.
europepmc   +1 more source

Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin‐1‐Mediated PI3K/AKT Signaling Pathway in Cisplatin‐Resistant Cervical Cancer Cells

The FASEB Journal, Volume 40, Issue 9, 15 May 2026.
Simvastatin synergizes with cisplatin in cisplatin‐resistant cervical cancer cells through suppression of the caveolin‐1‐mediated PI3K/AKT signaling axis. ABSTRACT Cervical cancer treatment is often hindered by the emergence of cisplatin (DDP) resistance. Increasing evidence has indicated that statins possess anti‐tumor and chemosensitization potential
Yujia Zhou, Hejing Liu, Shuangjia Pan, Luyi Ruan, Jiayi Ruan, Jiaru Chen, Huihui Ji, Xueqiong Zhu   +7 more
wiley   +1 more source

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001 [PDF]

, 2017
Uy, Geoffrey L., Westervelt, Peter
core   +1 more source